Ovid Stops Development and Testing of OV101 for Fragile X

Ovid Stops Development and Testing of OV101 for Fragile X

292750

Ovid Stops Development and Testing of OV101 for Fragile X

Ovid Therapeutics announced it is discontinuing work to further develop or test OV101 (gaboxadol) as a potential treatment of fragile X syndrome. Although OV101 was found to be safe and well tolerated in multiple clinical trials, its overall efficacy in these studies fell short, Ovid Therapeutics said in a press release. The company now plans to shift its focus to the development of its early stage pipeline, which include OV882, a short hairpin RNA (shRNA) therapy…

You must be logged in to read/download the full post.